This is an old revision of the document!

Preliminary Report - ID Mapping

Traditionally the BioGRID repository has required that all curated data map to a peer-reviewed Pubmed ID before public release. With the rapidly evolving global health crisis of COVID-19, we've decided to temporarily suspend that requirement in order to more rapidly curate publications released on platforms such as BiorXiv and provide that data to the research community. As a result, some of our download files currently require a Pubmed ID to output correctly (such as PSI-MI TAB, BioGRID TAB2, and PSI-MI XML). We recommend anyone wanting to get the most accurate download available to please use our newest TAB3 format instead.

In order to maintain compatibility, we've temporarily assigned new custom IDs in place of Pubmed IDs for each of these publications. So, if you see one of these IDs, you can use the following listing to determine the associated DOI for each.

WARNING - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

Custom ID	DOI	AUTHOR	DATASET
888800000002	10.1101/2020.03.29.20041962	Gao T (2020)	Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
888800000003	10.1101/2020.02.16.951723	Sun C (2020)	SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
888800000005	10.1101/2020.03.14.988345	Wang K (2020)	SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
888800000006	10.1101/2020.02.17.951848	Zhou Q (2020)	Structure of dimeric full-length human ACE2 in complex with B0AT1
888800000007	10.1101/2020.02.26.964882	Jin Z (2020)	Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]
888800000008	10.1101/2020.03.29.013490	Wang C (2020)	Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
888800000009	10.1101/2020.03.25.996348	Dai W (2020)	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
888800000010	10.1101/2020.03.15.992883	Joyce MG (2020)	A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
888800000011	10.1101/2020.03.16.993386	Gao Y (2020)	Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target
888800000012	10.1101/2020.03.31.019216	Liang Q (2020)	Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis
888800000013	10.1101/2020.04.15.042085	Bestle D (2020)	TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
888800000016	10.1101/2020.04.14.042010	Chi X (2020)	Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
888800000017	10.1101/2020.04.06.20055475	Ye L (2020)	Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
888800000018	10.1101/2020.04.19.049643	Zeng X (2020)	Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
888800000019	10.1101/2020.04.23.057265	Peng Q (2020)	Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus
888800000020	10.1101/2020.04.22.046565	Liu Y (2020)	Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2
888800000021	10.1101/2020.04.21.053017	Walker A (2020)	Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
888800000022	10.1101/2020.04.17.047498	Rosas Lemus M (2020)	The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine
888800000025	10.1101/2020.04.29.068890	Rut W (2020)	Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design
888800000029	10.1101/2020.05.02.20086876	Zhang D (2020)	Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)
888800000031	10.1101/2020.05.06.079830	Zha L (2020)	Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
888800000032	10.1101/2020.05.02.043554	Gunther S (2020)	Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
888800000033	10.1101/2020.05.01.20077743	Wu Y (2020)	A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
888800000034	10.1101/2020.05.03.074914	Liu X (2020)	Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
888800000035	10.1101/2020.05.21.109157	Lui I (2020)	Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
888800000036	10.1101/2020.05.21.107870	Partridge LJ (2020)	Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line
888800000037	10.1101/2020.05.13.092478	Chiodo F (2020)	Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota
888800000038	10.1101/2020.05.12.091298	Seydoux E (2020)	Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
888800000039	10.1101/2020.05.21.107565	Zang J (2020)	Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
888800000040	10.1101/2020.05.12.092171	Zhou X (2020)	Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation
888800000041	10.1101/2020.06.17.156455	Stukalov A (2020)	Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV
888800000042	10.1101/2020.06.05.135921	Bertoglio F (2020)	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
888800000043	10.1101/2020.06.05.135699	Moustaqil M (2020)	SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.
888800000045	10.1101/2020.06.05.134114	Daly JL (2020)	Neuropilin-1 is a host factor for SARS-CoV-2 infection
888800000046	10.1101/2020.06.17.158121	Cubuk J (2020)	The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
888800000048	10.1101/2020.06.02.130161	Hanke L (2020)	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
888800000049	10.1101/2020.06.17.156471	Conceicao C (2020)	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
888800000050	10.1101/2020.06.07.138677	Luan X (2020)	Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376
888800000051	10.1101/2020.06.02.129098	Lv Z (2020)	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
888800000052	10.1101/2020.06.06.137513	Lou Y (2020)	Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
888800000053	10.1101/2020.05.27.118117	Douangamath A (2020)	Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
888800000054	10.1101/2020.06.16.155812	Li J (2020)	Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
888800000055	10.1101/2020.06.15.153387	Beddingfield B (2020)	The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
888800000056	10.1101/2020.06.16.154708	Hanson QM (2020)	Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
888800000057	10.1101/2020.06.09.20127050	Gniffke EP (2020)	Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
888800000058	10.1101/2020.06.25.172403	Zhao P (2020)	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor
888800000059	10.1101/2020.07.07.191676	Schubert K (2020)	SARS-CoV-2 Nsp1 binds ribosomal mRNA channel to inhibit translation
888800000060	10.1101/2020.07.01.182659	Lu J (2020)	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity
888800000061	10.1101/2020.06.27.174979	Ke Z (2020)	Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virions
888800000062	10.1101/2020.07.04.187757	Yurkovetskiy L (2020)	Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
888800000063	10.1101/2020.07.31.230730	Cao W (2020)	Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction
888800000064	10.1101/2020.07.24.219857	Esparza TJ (2020)	High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
888800000065	10.1101/2020.07.25.221036	Shilts J (2020)	No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
888800000066	10.1101/2020.07.13.201517	Davies JP (2020)	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies
888800000067	10.1101/2020.07.31.229781	Alitongbieke G (2020)	Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2
888800000068	10.1101/2020.07.31.231746	Glasgow A (2020)	Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
888800000069	10.1101/2020.07.27.224089	Beasley MD (2020)	Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
888800000070	10.1101/2020.07.29.227462	Gao C (2020)	SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors
888800000071	10.1101/2020.07.26.222026	Zheng Y (2020)	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling
888800000072	10.1101/2020.07.30.229187	Shi W (2020)	A dynamic regulatory interface on SARS-CoV-2 RNA polymerase
888800000073	10.1101/2020.07.14.201616	Clausen TM (2020)	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
888800000074	10.1101/2020.07.29.226761	ElBaba TJ (2020)	Allosteric inhibition of the SARS-CoV-2 main protease - insights from mass spectrometry-based assays
888800000075	10.1101/2020.07.15.204404	Schmidt N (2020)	A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells
888800000076	10.1101/2020.08.03.234914	Cao L (2020)	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
888800000077	10.1101/2020.07.27.223727	Sacco MD (2020)	Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L
888800000078	10.1101/2020.07.17.208959	Fu Z (2020)	Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
888800000079	10.1101/2020.07.31.231282	Tee KL (2020)	Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay
888800000080	10.1101/2020.07.25.220806	Temerozo JR (2020)	The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.